Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • BI 11054 - Healthy
    Clinical Study Number 1250.1
    Study Indication Healthy
    Product BI 11054
    Generic Name BI 11054
    Lab Code
    Clinical Phase I
    Study Title

    A randomised, double-blind, placebo-controlled (within dose groups) study to assess safety, tolerability, and pharmacokinetics of single rising inhaled doses (0.5 µg to 70 µg administered with Respimat®) of BI 11054 CL in healthy male volunteers

    Study Document
    Trial synopsis 1250.1 english